Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 54 15 71
Papillomatosis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 43 D010212
NCIt 49 C3713 C7440
SNOMED-CT 67 23730008 82049002
UMLS 71 C0030354 C0205875

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to squamous cell papilloma and intraductal papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Metformin and Bethanechol have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1078)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 34.9 TP53 KRT14
2 intraductal papilloma 34.6 TP63 KRT5 KRT14
3 bladder transitional cell papilloma 34.6 TP53 KRT20 CDKN1A
4 urinary bladder inverted papilloma 34.5 RB1 CDKN2A
5 inverted papilloma 34.5 TP53 KRT5 KRT20 KRT13 CDKN2A AMOT
6 frontal sinus inverted papilloma 34.5 KRT5 KRT13
7 subareolar duct papillomatosis 34.5 KRT8 KRT5
8 inverted transitional papilloma 34.5 KRT5 CDKN2A
9 skin papilloma 34.0 TP53 PTEN KRT14 KRT10 CDKN1A
10 oral cancer 33.3 TP53 KRT13 CDKN2A
11 anogenital venereal wart 33.2 UBE3A TP53 RB1 CDKN2A
12 penile cancer 33.1 TP53 PTEN CDKN2A
13 bladder benign neoplasm 32.6 RB1 KRT20 CDKN2A
14 palmoplantar keratoderma, epidermolytic 32.5 KRT5 KRT14 KRT10 FLG
15 keratosis, seborrheic 32.5 TP53 KRT5 KRT10 IVL CDKN2A
16 li-fraumeni syndrome 32.4 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
17 cervix uteri carcinoma in situ 32.1 TP53 RB1 CDKN2A
18 suppressor of tumorigenicity 3 32.0 UBE3A TP53 RB1 CDKN2A CDKN1A
19 cervical intraepithelial neoplasia 31.9 KRT8 IVL CDKN2A
20 anus cancer 31.5 UBE3A TP53 CDKN2A
21 in situ carcinoma 31.5 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
22 familial retinoblastoma 31.5 TP53 RB1 CDKN2A
23 squamous cell carcinoma 31.5 TP63 TP53 RB1 PTEN KRT13 IVL
24 transitional cell carcinoma 31.4 TP63 TP53 PTEN KRT8 KRT20 CDKN2A
25 cervical cancer 31.4 UBE3A TP63 TP53 RB1 PTEN KRT14
26 adenocarcinoma 31.3 TP53 RB1 PTEN KRT20 CDKN2A CDKN1A
27 cervical squamous cell carcinoma 31.2 TP63 TP53 KRT8 CDKN2A
28 oropharynx cancer 31.2 UBE3A TP53 PTEN KRT5 KRT14 CDKN2A
29 epidermodysplasia verruciformis 1 31.2 UBE3A TP53 RB1 KRT14
30 oral leukoplakia 31.2 TP63 TP53 CDKN2A
31 ductal carcinoma in situ 31.2 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
32 vulvar intraepithelial neoplasia 31.1 TP53 CDKN2A
33 esophagitis 31.1 TP53 IVL IL4 CDKN2A
34 bowenoid papulosis 31.1 FLG CDKN2A
35 verrucous carcinoma 31.1 TP53 PTEN KRT5 KRT10 CDKN2A
36 vaginal cancer 31.1 UBE3A TP53 CDKN2A
37 cholangiocarcinoma 31.0 TP53 PTEN KRT8 KRT20
38 papillary transitional carcinoma 31.0 TP53 KRT20
39 meningioma, familial 31.0 TP53 PTEN IGF2 CDKN2A AMOT
40 esophageal cancer 31.0 TP63 TP53 RB1 PTEN IGF2 CDKN2A
41 hard palate cancer 31.0 KRT5 KRT14 KRT13
42 keratosis 31.0 TP53 KRT5 KRT10 IVL FLG CDKN2A
43 skin carcinoma 31.0 TP53 KRT8 KRT20 IVL FLG CDKN2A
44 actinic keratosis 31.0 TP63 TP53 KRT20 FLG CDKN2A
45 nasopharyngeal carcinoma 31.0 TP53 PTEN KRT13 CDKN2A CDKN1A
46 intrahepatic cholangiocarcinoma 31.0 TP53 PTEN KRT20
47 breast fibroadenoma 30.9 TP53 KRT8 KRT14
48 bladder cancer 30.9 TP63 TP53 RB1 PTEN KRT8 KRT20
49 small cell carcinoma 30.9 TP53 PTEN KRT8 KRT20 CDKN2A
50 ameloblastoma 30.9 TP53 KRT8 KRT14

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CDKN1A CDKN2A PTEN RB1 TP53 UBE2L3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CDKN1A CDKN2A PTEN RB1 TP53 TP63

MGI Mouse Phenotypes related to Papilloma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
2 cellular MP:0005384 10.35 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
3 digestive/alimentary MP:0005381 10.34 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
4 cardiovascular system MP:0005385 10.32 AMOT CDKN1A CDKN2A IFNAR1 IGF2 KRT8
5 mortality/aging MP:0010768 10.31 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
6 endocrine/exocrine gland MP:0005379 10.28 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
7 integument MP:0010771 10.27 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
8 embryo MP:0005380 10.25 AMOT CDKN1A CDKN2A IGF2 KRT8 PTEN
9 immune system MP:0005387 10.25 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
10 craniofacial MP:0005382 10.17 CDKN1A IGF2 IL4 KRT14 KRT5 RB1
11 no phenotypic analysis MP:0003012 10.07 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT5
12 liver/biliary system MP:0005370 10.06 CDKN1A CDKN2A IGF2 IL4 KRT8 PTEN
13 limbs/digits/tail MP:0005371 10.02 CDKN1A IGF2 KRT5 PTEN RB1 TP53
14 neoplasm MP:0002006 10.01 CDKN1A CDKN2A IFNAR1 KRT14 PTEN RB1
15 reproductive system MP:0005389 9.93 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
16 renal/urinary system MP:0005367 9.86 CDKN1A IFNAR1 IGF2 IL4 PTEN RB1
17 pigmentation MP:0001186 9.72 CDKN2A KRT14 PTEN RB1 TP53
18 respiratory system MP:0005388 9.61 CDKN1A CDKN2A IGF2 IL4 KRT14 PTEN
19 vision/eye MP:0005391 9.32 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14

Drugs & Therapeutics for Papilloma

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Polihexanide Approved, Investigational Phase 4 28757-47-3
5
Cantharidin Approved, Investigational Phase 4 56-25-7
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
10
Dolutegravir Approved Phase 4 1051375-16-6 54726191
11
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
12
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
13 Muscarinic Agonists Phase 4
14 Hypoglycemic Agents Phase 4
15 Chlorhexidine gluconate Phase 4
16 Biguanides Phase 4
17 Disinfectants Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
20 MF59 oil emulsion Phase 4
21 Pharmaceutical Solutions Phase 4
22 Anti-Infective Agents Phase 4
23 Antiviral Agents Phase 4
24 Vaccines Phase 4
25 Anti-Retroviral Agents Phase 4
26
protease inhibitors Phase 4
27 HIV Protease Inhibitors Phase 4
28 Anti-HIV Agents Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Anti-Bacterial Agents Phase 4
32 insulin Phase 4
33 Insulin, Globin Zinc Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 HIV Integrase Inhibitors Phase 4
36 Integrase Inhibitors Phase 4
37
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
38
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
39
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
40
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
41
Histamine Approved, Investigational Phase 3 51-45-6 774
42
Azithromycin Approved Phase 3 83905-01-5 55185 447043
43
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
44
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
45
Promethazine Approved, Investigational Phase 3 60-87-7 4927
46
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
48
Zinc Approved, Investigational Phase 3 7440-66-6 32051
49
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
50
Cetuximab Approved Phase 3 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
2 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
3 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
4 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
5 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
8 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
9 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
10 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
11 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
12 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
13 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
14 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
15 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
16 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
17 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
18 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
19 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
20 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
21 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
22 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
23 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
24 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
25 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
26 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
27 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
28 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
29 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
30 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
31 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
32 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
33 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
34 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
35 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
36 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
37 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
38 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
39 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
40 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
41 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
42 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
43 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
44 Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process Completed NCT00169494 Phase 3
45 Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) Completed NCT00196924 Phase 3
46 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
47 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
48 A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age. Completed NCT00122681 Phase 3
49 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
50 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

40
Breast, Skin, Cervix, Testes, Lung, T Cells, Brain

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 16604)
# Title Authors PMID Year
1
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 54 61
20395210 2010
2
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 54 61
19621447 2009
3
Colonic adenoma with squamous metaplasia. 54 61
18701516 2009
4
Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. 54 61
18681909 2009
5
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. 54 61
19411857 2009
6
FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. 54 61
19287463 2009
7
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. 54 61
19060248 2009
8
Primary adenosquamous carcinoma of the colon: report of five cases. 54 61
19562453 2009
9
Identification of human papillomavirus in esophageal squamous papillomas. 54 61
19084918 2008
10
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 54 61
18958930 2008
11
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. 54 61
18300235 2008
12
Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9. 54 61
17920185 2008
13
Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. 54 61
19516893 2008
14
On the mechanism of phenotypic conversion of human cervical adenocarcinoma HeLa cells surviving infection by influenza B virus: potential implications for biological management of adenocarcinomas. 54 61
18291599 2008
15
[Efficacy of local use of recombinant interferon alpha-2 preparations in combined treatment of recurrent respiratory papillomatosis]. 54 61
18833124 2008
16
Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. 54 61
18180113 2008
17
Overexpression of p27kip1 in urinary bladder urothelial carcinoma. 54 61
18036045 2007
18
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. 54 61
17977825 2007
19
Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. 54 61
17855174 2007
20
Carotenoids suppress proliferating cell nuclear antigen and cyclin D1 expression in oral carcinogenic models. 54 61
17369034 2007
21
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 54 61
17638654 2007
22
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. 54 61
17116360 2007
23
The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. 54 61
17367326 2007
24
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. 54 61
17551924 2007
25
A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. 54 61
17489063 2007
26
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 54 61
17847937 2007
27
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 54 61
17294450 2007
28
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 54 61
17685229 2007
29
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). 54 61
17131388 2007
30
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 54 61
17545048 2007
31
Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 54 61
17414102 2007
32
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 54 61
17295644 2007
33
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 54 61
16698948 2007
34
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 54 61
17376306 2007
35
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 54 61
17277618 2007
36
The history of the angiogenic switch concept. 54 61
16990761 2007
37
[Risk factors and clinical characteristic patients with vulvar cancer]. 54 61
17373116 2006
38
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 54 61
16965327 2006
39
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 54 61
16845792 2006
40
Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. 54 61
16624261 2006
41
Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. 54 61
16703747 2006
42
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. 54 61
16624193 2006
43
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. 54 61
16205640 2006
44
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 54 61
17310826 2006
45
Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. 54 61
19771278 2006
46
Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. 54 61
16979303 2006
47
Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. 54 61
16998598 2006
48
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. 54 61
16142387 2005
49
Markers of malignant transformation of sinonasal inverted papilloma. 54 61
16005600 2005
50
Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. 54 61
16120114 2005

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
2
Show member pathways
12.84 UBE3A TP53 RB1 PTEN IL4 IGF2
3
Show member pathways
12.77 TP63 TP53 IGF2 CDKN2A CDKN1A
4
Show member pathways
12.75 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
5
Show member pathways
12.64 TP53 RB1 PTEN CDKN2A CDKN1A
6 12.58 TP53 RB1 PTEN IL4 IGF2 IFNAR1
7 12.52 TP63 TP53 PTEN CDKN2A CDKN1A
8 12.5 TP63 TP53 RB1 CDKN2A CDKN1A
9 12.46 KRT8 KRT5 KRT20 KRT13 KRT10 AMOT
10
Show member pathways
12.39 TP53 PTEN IL4 IGF2 CDKN1A
11
Show member pathways
12.36 TP53 RB1 PTEN CDKN2A CDKN1A
12 12.33 TP53 RB1 CDKN2A CDKN1A
13
Show member pathways
12.31 TP53 RB1 CDKN2A CDKN1A
14 12.3 TP53 RB1 PTEN CDKN2A CDKN1A
15
Show member pathways
12.25 TP53 RB1 IL4 IGF2 IFNAR1
16 12.25 UBE3A TP53 RB1 CDKN2A CDKN1A
17
Show member pathways
12.22 TP53 RB1 PTEN CDKN1A
18 12.11 TP53 RB1 PTEN CDKN2A CDKN1A
19 11.98 TP53 PTEN CDKN2A CDKN1A
20 11.98 TP63 TP53 RB1 PTEN CDKN1A
21
Show member pathways
11.95 KRT8 KRT5 KRT14 KRT13
22 11.88 KRT20 KRT14 KRT13 KRT10
23 11.85 TP53 RB1 PTEN CDKN1A
24 11.84 UBE3A RB1 PTEN CDKN1A
25 11.8 TP53 RB1 CDKN1A
26 11.79 TP53 RB1 PTEN CDKN2A CDKN1A
27 11.78 TP63 TP53 PTEN
28 11.7 TP53 CDKN2A CDKN1A
29 11.7 TP53 RB1 CDKN2A CDKN1A
30
Show member pathways
11.68 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
31 11.65 UBE3A TP53 RB1 CDKN2A CDKN1A
32 11.63 TP53 KRT5 KRT14 IL4 CDKN1A
33 11.49 TP53 RB1 CDKN2A CDKN1A
34 11.48 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
35 11.4 TP53 RB1 PTEN CDKN1A
36 11.09 TP53 RB1 CDKN2A
37
Show member pathways
10.8 TP63 TP53 CDKN2A CDKN1A
38 10.75 TP53 CDKN1A
39
Show member pathways
10.56 TP53 CDKN1A

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.2 UBE3A UBE2L3 TP63 TP53 RB1 PTEN
2 cytosol GO:0005829 9.86 UBE3A UBE2L3 TP63 TP53 PTEN KRT8
3 keratin filament GO:0045095 9.46 KRT8 KRT5 KRT14 KRT13
4 cornified envelope GO:0001533 9.43 KRT10 IVL FLG
5 intermediate filament GO:0005882 9.17 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 UBE3A TP63 TP53 RB1 IL4 IGF2
2 apoptotic process GO:0006915 10.01 TP63 TP53 RB1 PTEN KRT20 CDKN2A
3 negative regulation of cell proliferation GO:0008285 9.98 TP53 RB1 PTEN CDKN2A CDKN1A
4 cell proliferation GO:0008283 9.89 UBE2L3 TP63 TP53 PTEN
5 protein stabilization GO:0050821 9.85 TP53 PTEN CDKN2A CDKN1A
6 regulation of cell cycle GO:0051726 9.81 TP53 RB1 PTEN CDKN1A
7 cell cycle arrest GO:0007050 9.78 TP53 RB1 CDKN2A CDKN1A
8 neuron apoptotic process GO:0051402 9.67 TP63 TP53 RB1
9 Ras protein signal transduction GO:0007265 9.67 TP53 RB1 CDKN2A CDKN1A
10 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.63 PTEN CDKN2A CDKN1A
11 response to arsenic-containing substance GO:0046685 9.62 PTEN CDKN1A
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.62 RB1 PTEN CDKN2A CDKN1A
13 hemidesmosome assembly GO:0031581 9.61 KRT5 KRT14
14 hepatocyte apoptotic process GO:0097284 9.61 RB1 KRT8
15 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.61 TP63 TP53 CDKN1A
16 response to UV-B GO:0010224 9.6 TP53 IVL
17 peptide cross-linking GO:0018149 9.58 KRT10 IVL FLG
18 negative regulation of dendritic spine morphogenesis GO:0061002 9.57 UBE3A PTEN
19 prostate gland growth GO:0060736 9.56 UBE3A PTEN
20 signal transduction by p53 class mediator GO:0072331 9.52 TP53 CDKN1A
21 keratinization GO:0031424 9.5 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
22 keratinocyte differentiation GO:0030216 9.46 TP63 KRT10 IVL FLG
23 replicative senescence GO:0090399 9.43 TP53 CDKN2A CDKN1A
24 cornification GO:0070268 9.23 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 UBE3A UBE2L3 TP63 TP53 RB1 PTEN
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN1A
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP63 TP53
4 disordered domain specific binding GO:0097718 9.13 TP53 RB1 CDKN2A

Sources for Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....